Poor
Not Aligned
Patient Risk:
Medium
Summary
Most claims about hepatic adverse effects and indications align with the supplied label excerpts, but at least one claim (via the provided evaluation claims) introduces an unlabel-supported indication expansion beyond the specific CABP organisms listed in the label, making overall alignment poor.
Category Scores
Accurate Statements
Tigecycline is a glycylcycline antibiotic.
Not supportable from the supplied label excerpts provided in the prompt.
Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
Not supportable from the supplied label excerpts provided in the prompt (approval year not shown).
Tigecycline was approved by the FDA in 2005 for the treatment of community-acquired bacterial pneumonia (CABP).
Not supportable from the supplied label excerpts provided in the prompt (approval year not shown).
Liver enzyme elevation is a common adverse effect associated with tigecycline use.
Supported generally by the label excerpt describing hepatic adverse effects (increases in transaminases/transaminases) but the excerpt does not provide frequency specifically for 'common'.
Regular liver function tests, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), should be performed in patients receiving tigecycline.
Partially supported: the label excerpt says abnormal liver function tests should be monitored, but ALT/AST and 'should be performed' is not explicitly stated in the supplied excerpt.
Unsupported Statements
Liver enzyme elevation occurred in 12.1% of patients receiving tigecycline in a study in the Journal of Clinical Pharmacology.
Not supported by the supplied label excerpts (no such percentage or source journal included).
Liver enzyme elevation occurred in 21.4% of patients receiving tigecycline for cSSSI in a study published in the Journal of Antimicrobial Chemotherapy.
Not supported by the supplied label excerpts (no such percentage or source journal included).
Liver enzyme elevation occurred in 15.6% of patients receiving tigecycline for CABP in a study published in the Journal of Clinical Pharmacology.
Not supported by the supplied label excerpts (no such percentage or source journal included).
A review of postmarketing surveillance data from the FDA found liver enzyme elevation occurred in 10.3% of patients receiving tigecycline.
Not supported by the supplied label excerpts (postmarketing section provided lists identified adverse reactions without frequencies).
Older adults are at increased risk of liver enzyme elevation with tigecycline use.
The provided geriatric excerpt indicates no overall differences in safety/effectiveness; it does not state increased risk for liver enzyme elevation in older adults.
Patients with renal impairment are at increased risk of liver enzyme elevation with tigecycline use.
No renal impairment/hepatic risk statement is present in the supplied label excerpts.
Concomitant use of other medications that can cause liver enzyme elevation (e.g., statins and antiretroviral medications) may increase the risk of liver enzyme elevation with tigecycline use.
No drug-interaction or statin/antiretroviral-specific hepatotoxicity risk statement is present in the supplied label excerpts.
Patients should be monitored for clinical symptoms of liver damage, including jaundice, fatigue, and abdominal pain.
The label excerpt mentions monitoring for evidence of worsening hepatic function and includes that hepatic dysfunction may occur after discontinuation; it does not list 'fatigue' or 'abdominal pain' or provide symptom monitoring guidance in the supplied text.
The most common liver enzyme elevation associated with tigecycline use is an increase in alanine aminotransferase (ALT) levels.
The supplied table shows SGOT/SGPT increased but does not establish which is 'most common' nor explicitly states ALT as most common.
In some cases, liver enzyme elevation with tigecycline use can be reversed by discontinuing the medication or reducing the dose.
The supplied hepatic adverse effects excerpt does not state reversibility by discontinuing or dose reduction.
Contradictions
High
AI Statement
TYGACIL can be used for community-acquired bacterial pneumonia caused by organisms other than Streptococcus pneumoniae (penicillin-susceptible isolates), Haemophilus influenzae, and Legionella pneumophila, as long as the isolates are susceptible.
Label Reference
CABP indication excerpt (1.3) lists specific susceptible isolates (Streptococcus pneumoniae penicillin-susceptible, including concurrent bacteremia; Haemophilus influenzae; Legionella pneumophila). The 'other organisms' expansion is not supported by the supplied 1.3 excerpt.
Important Omissions
Contraindications, boxed warnings, and specific drug interaction instructions are not evaluated because the provided claim set does not include them and the provided label excerpts do not contain those sections.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
The indication expansion beyond label-listed CABP organisms (even if presented as a generalization) is potentially clinically consequential. Several other numeric and risk-factor claims are unsupported by the provided label excerpts, which could mislead risk assessment/monitoring emphasis.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unlabel-supported expansion of CABP organisms beyond those explicitly listed in the provided label excerpt (1.3).
Suggested Improvement
Restrict CABP indication organism statements to those explicitly listed in label section 1.3; avoid adding unspecified additional organisms and avoid citing specific percentage frequencies or FDA postmarketing incidence figures unless present in the supplied label text.